iTeos Therapeutics, Inc. (ITOS)
| Market Cap | 241.39M |
| Revenue (ttm) | 35.00M |
| Net Income (ttm) | -134.41M |
| Shares Out | 38.19M |
| EPS (ttm) | -3.32 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 145,527 |
| Open | 6.71 |
| Previous Close | 6.71 |
| Day's Range | 6.30 - 6.80 |
| 52-Week Range | 6.30 - 18.75 |
| Beta | 1.38 |
| Analysts | Strong Buy |
| Price Target | 26.00 (+311.39%) |
| Earnings Date | Mar 5, 2025 |
About ITOS
iTeos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company’s lead antibody product candidate, belrestotug, an antagonist of T-cell immunoreceptor with Ig and ITIM domains (TIGIT), as well as engages the Fc gamma receptor to activate dendritic cells, natural killer cells, T lymphocytes, and macrophages and to promote the release of cytotoxic granules and antibody-dependent cellular cytotoxicity activity. Its product pipeline ... [Read more]
Financial Performance
In 2024, iTeos Therapeutics's revenue was $35.00 million, an increase of 177.89% compared to the previous year's $12.60 million. Losses were -$134.41 million, 19.3% more than in 2023.
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for ITOS stock is "Strong Buy." The 12-month stock price forecast is $26.0, which is an increase of 311.39% from the latest price.
News
iTeos to Present Preclinical Data on Potential Best-In-Class Anti-TREM2 Antibody, EOS-215, and Novel PTPN1/2 Inhibitor at the American Association for Cancer Research Annual Meeting 2025
WATERTOWN, Mass. and GOSSELIES, Belgium, March 25, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development...
iTeos Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
- Topline interim dataset from GALAXIES Lung-201 with >240 patients anticipated in 2Q25 - Interim datasets from GALAXIES H&N-202 and TIG-006 HNSCC with ~200 patients anticipated in 2025 - Completed en...
iTeos Therapeutics: Decimated By Collateral Events, Good Chances Of Success Nevertheless
iTeos' lead molecule, Belrestotug, shows promising efficacy in trials despite setbacks in the anti-TIGIT space, with significant partnerships and a strong cash position. The stock has suffered due to ...
iTeos Therapeutics: A Perhaps Unjustified Decline To End 2024
iTeos Therapeutics, Inc.'s lead candidate, belrestotug, shows promising response rates in lung cancer but faces challenges with increased toxicity and skepticism due to past failures in similar approa...
iTeos Therapeutics Presents Interim A2A-005 Clinical Trial Data, Translational, and Preclinical Data from Inupadenant at ESMO Immuno-Oncology Congress
- Inupadenant + carboplatin/pemetrexed in Phase 2 A2A-005 trial demonstrated a 63.9% overall response rate (ORR) and a median PFS of 7.7 months for all evaluable patients across the cohorts - Recommen...
iTeos to Participate in Upcoming Investor Conferences
WATERTOWN, Mass. and GOSSELIES, Belgium, Nov. 26, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development ...
iTeos Reports Third Quarter 2024 Financial Results and Provides Business Updates
- EMA granted clearance to advance belrestotug 400mg + dostarlimab as recommended Phase 3 dose and activate GALAXIES Lung-301 clinical sites in the EU - Interim data from inupadenant Phase 2 A2A-005 i...
iTeos Therapeutics, Upstart Holdings And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were mixed this morning, with the Dow futures gaining around 100 points on Monday.
iTeos Therapeutics: ESMO Data Showing Signs Of A Real Win For TIGIT
iTeos Therapeutics' belrestotug shows promising response rates in lung cancer trials, especially when combined with dostarlimab, despite significant safety concerns. Financially, ITOS has over 3 years...
iTeos Announces Clinically Meaningful Objective Response Rate Observed at Every Dose in Follow-up Interim Analysis of GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients
- Clinically meaningful objective response rate (ORR) of 63.3-76.7% observed with belrestotug + dostarlimab combinations, with confirmed ORR (cORR) at ~60% for every dose - >30% cORR difference betwee...
iTeos Therapeutics Announces Late-Breaking Oral Presentation of Phase 2 GALAXIES Lung-201 Interim Data at the European Society for Medical Oncology Congress 2024
WATERTOWN, Mass. and GOSSELIES, Belgium, Aug. 20, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS) (“iTeos”), a clinical-stage biopharmaceutical company pioneering the discovery and de...
iTeos Therapeutics Announces Appointment of David Feltquate as Chief Medical Officer
WATERTOWN, Mass. and GOSSELIES, Belgium, Aug. 05, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS) (“iTeos”), a clinical-stage biopharmaceutical company pioneering the discovery and d...
iTeos Therapeutics: Rippling Waves Of TIGIT Pessimism
iTeos Therapeutics is developing an anti-TIGIT molecule for various cancers, partnering with GSK and advancing to late-stage clinical studies. Their main clinical focus is belrestotug, aiming to diffe...
iTeos Announces First Patient Dosed in GALAXIES Lung-301 Phase 3 Study, Earning $35 Million in Milestones from GSK
WATERTOWN, Mass. and GOSSELIES, Belgium, July 08, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS) (“iTeos”), a clinical-stage biopharmaceutical company pioneering the discovery and de...
iTeos and GSK Initiate GALAXIES Lung-301 Phase 3 Study, Assessing Belrestotug and Dostarlimab in Previously Untreated, Unresectable Locally Advanced / Metastatic PD-L1 Selected Non-Small Cell Lung Cancer
WATERTOWN, Mass. and GOSSELIES, Belgium, June 17, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS) (“iTeos”), a clinical-stage biopharmaceutical company pioneering the discovery and de...
iTeos Therapeutics to raise $120 million via registered direct offering
iTeos Therapeutics Inc (NASDAQ: ITOS) is up 30% today after announcing plans of a registered direct offering. iTeos Therapeutics stock pops on Q1 earnings The biotechnology company will sell a total ...
iTeos Reports First Quarter 2024 Financial Results and Provides Business Updates
- Belrestotug + dostarlimab exceeded pre-defined efficacy criteria for clinically relevant activity observed in an interim assessment of Phase 2 GALAXIES Lung-201 - Clinically meaningful tumor reducti...
iTeos Therapeutics Announces $120 Million Registered Direct Offering
- Led by existing investors RA Capital Management and Boxer Capital - Purchase price of $17.50 represents a premium of approximately 44% to last close - Further strengthens balance sheet with pro form...
iTeos Presents EOS-984 Preclinical Data Demonstrating Restoration of T Cell Activity from Adenosine Suppression at the American Association for Cancer Research Annual Meeting 2024
WATERTOWN, Mass. and GOSSELIES, Belgium, April 07, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development...
iTeos Appoints Oncology Veteran Jill DeSimone to Its Board of Directors
WATERTOWN, Mass. and GOSSELIES, Belgium, March 06, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development...
iTeos Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
- Multiple clinical milestones across portfolio anticipated in 2024, including two Phase 2 trials assessing belrestotug + dostarlimab in 1L NSCLC and 1L HNSCC - Completed enrollment of third dose coho...
iTeos to Highlight Preclinical Data on First-In-Class EOS-984 Targeting ENT1 at the American Association for Cancer Research Annual Meeting 2024
WATERTOWN, Mass. and GOSSELIES, Belgium, March 05, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development...
iTeos to Present at the Piper Sandler 35th Annual Healthcare Conference
WATERTOWN, Mass. and GOSSELIES, Belgium, Nov. 21, 2023 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development ...
iTeos Reports Third Quarter 2023 Financial Results and Provides Business Updates
- Initiation of GALAXIES H&N-202, a Phase 2 platform study assessing TIGIT:PD-1 doublet and other novel IO combinations, including a CD96 triplet in HNSCC - Completed enrollment of monotherapy dose e...